Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor ventricular remodeling after myocardial infarction in rats

Detalhes bibliográficos
Autor(a) principal: Zornoff, Leonardo A.M. [UNESP]
Data de Publicação: 2000
Outros Autores: Paiva, Sérgio A.R. [UNESP], Matsubara, Beatriz B. [UNESP], Matsubara, Luiz S. [UNESP], Spadaro, Joel [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1054/JCPT.2000.7450
http://hdl.handle.net/11449/224157
Resumo: Background: There are limited data regarding the effects of angiotensin II receptor blockade after myocardial infarction (MI). In addition, whether combined angiotensin converting enzyme (ACE) inhibitor and angiotensin II type I (AT1) receptor antagonist may be superior to either drug alone on ventricular remodeling remains unclear. The goal of this study was to determine if the cardiac effects of the combined administration of an ACE inhibitor and AT1 receptor antagonist are greater than those produced by either of these agents administered individually after MI. Methods and Results: After MI, rats were divided into 4 groups: 1) untreated animals, 2) lisinopril treatment (20 mg/kg/day), 3) losartan treatment (20 mg/kg/day), and 4) lisinopril plus losartan treatment. After 3 months, the cardiac parameters studied were: mortality, fibrosis (hydroxyproline), hypertrophy (ventricular weight/body weight ratio [VW/BW]), left ventricular enlargement (volume at end-diastolic pressure equaled zero/body weight ratio [VO/BW]), and ventricular function (isovolumetric developed pressure, dp/dt, -dp/dt). A lowest mortality rate in the animals treated with the combination of both ACE inhibitor and AT1 receptor antagonist was observed. Although lisinopril and losartan significantly decreased VW/BW ratio, when administered concomitantly, VW/BW ratio was lower than when either agent was administered individually. There were no differences in right ventricle hydroxyproline concentration. Only combination therapy decreased VO/BW ratio. The treatment with lisinopril plus losartan resulted in increases in the development of pressure versus untreated group; without alteration in dp/dt and -dp/dt. Conclusions: The combination of the AT1 receptor blockade and ACE inhibitor is more effective than individual treatment on ventricular remodeling and survival after MI in rats.
id UNSP_9923dbcf70ff14c091fc3469549c0b01
oai_identifier_str oai:repositorio.unesp.br:11449/224157
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor ventricular remodeling after myocardial infarction in ratsLisinoprilLosartanMortalityMyocardial ischemiaBackground: There are limited data regarding the effects of angiotensin II receptor blockade after myocardial infarction (MI). In addition, whether combined angiotensin converting enzyme (ACE) inhibitor and angiotensin II type I (AT1) receptor antagonist may be superior to either drug alone on ventricular remodeling remains unclear. The goal of this study was to determine if the cardiac effects of the combined administration of an ACE inhibitor and AT1 receptor antagonist are greater than those produced by either of these agents administered individually after MI. Methods and Results: After MI, rats were divided into 4 groups: 1) untreated animals, 2) lisinopril treatment (20 mg/kg/day), 3) losartan treatment (20 mg/kg/day), and 4) lisinopril plus losartan treatment. After 3 months, the cardiac parameters studied were: mortality, fibrosis (hydroxyproline), hypertrophy (ventricular weight/body weight ratio [VW/BW]), left ventricular enlargement (volume at end-diastolic pressure equaled zero/body weight ratio [VO/BW]), and ventricular function (isovolumetric developed pressure, dp/dt, -dp/dt). A lowest mortality rate in the animals treated with the combination of both ACE inhibitor and AT1 receptor antagonist was observed. Although lisinopril and losartan significantly decreased VW/BW ratio, when administered concomitantly, VW/BW ratio was lower than when either agent was administered individually. There were no differences in right ventricle hydroxyproline concentration. Only combination therapy decreased VO/BW ratio. The treatment with lisinopril plus losartan resulted in increases in the development of pressure versus untreated group; without alteration in dp/dt and -dp/dt. Conclusions: The combination of the AT1 receptor blockade and ACE inhibitor is more effective than individual treatment on ventricular remodeling and survival after MI in rats.Departamento de Clínica Médica Faculdade de Medicina de Botucatu Universidade Estadual PaulistaDepartamento de Clínica Médica Faculdade de Medicina de Botucatu Universidade Estadual PaulistaUniversidade Estadual Paulista (UNESP)Zornoff, Leonardo A.M. [UNESP]Paiva, Sérgio A.R. [UNESP]Matsubara, Beatriz B. [UNESP]Matsubara, Luiz S. [UNESP]Spadaro, Joel [UNESP]2022-04-28T19:54:58Z2022-04-28T19:54:58Z2000-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article203-209http://dx.doi.org/10.1054/JCPT.2000.7450Journal of Cardiovascular Pharmacology and Therapeutics, v. 5, n. 3, p. 203-209, 2000.1074-2484http://hdl.handle.net/11449/22415710.1054/JCPT.2000.74502-s2.0-0033915319Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengJournal of Cardiovascular Pharmacology and Therapeuticsinfo:eu-repo/semantics/openAccess2022-04-28T19:54:58Zoai:repositorio.unesp.br:11449/224157Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462022-04-28T19:54:58Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor ventricular remodeling after myocardial infarction in rats
title Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor ventricular remodeling after myocardial infarction in rats
spellingShingle Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor ventricular remodeling after myocardial infarction in rats
Zornoff, Leonardo A.M. [UNESP]
Lisinopril
Losartan
Mortality
Myocardial ischemia
title_short Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor ventricular remodeling after myocardial infarction in rats
title_full Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor ventricular remodeling after myocardial infarction in rats
title_fullStr Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor ventricular remodeling after myocardial infarction in rats
title_full_unstemmed Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor ventricular remodeling after myocardial infarction in rats
title_sort Combination therapy with angiotensin converting enzyme inhibition and AT1 receptor inhibitor ventricular remodeling after myocardial infarction in rats
author Zornoff, Leonardo A.M. [UNESP]
author_facet Zornoff, Leonardo A.M. [UNESP]
Paiva, Sérgio A.R. [UNESP]
Matsubara, Beatriz B. [UNESP]
Matsubara, Luiz S. [UNESP]
Spadaro, Joel [UNESP]
author_role author
author2 Paiva, Sérgio A.R. [UNESP]
Matsubara, Beatriz B. [UNESP]
Matsubara, Luiz S. [UNESP]
Spadaro, Joel [UNESP]
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (UNESP)
dc.contributor.author.fl_str_mv Zornoff, Leonardo A.M. [UNESP]
Paiva, Sérgio A.R. [UNESP]
Matsubara, Beatriz B. [UNESP]
Matsubara, Luiz S. [UNESP]
Spadaro, Joel [UNESP]
dc.subject.por.fl_str_mv Lisinopril
Losartan
Mortality
Myocardial ischemia
topic Lisinopril
Losartan
Mortality
Myocardial ischemia
description Background: There are limited data regarding the effects of angiotensin II receptor blockade after myocardial infarction (MI). In addition, whether combined angiotensin converting enzyme (ACE) inhibitor and angiotensin II type I (AT1) receptor antagonist may be superior to either drug alone on ventricular remodeling remains unclear. The goal of this study was to determine if the cardiac effects of the combined administration of an ACE inhibitor and AT1 receptor antagonist are greater than those produced by either of these agents administered individually after MI. Methods and Results: After MI, rats were divided into 4 groups: 1) untreated animals, 2) lisinopril treatment (20 mg/kg/day), 3) losartan treatment (20 mg/kg/day), and 4) lisinopril plus losartan treatment. After 3 months, the cardiac parameters studied were: mortality, fibrosis (hydroxyproline), hypertrophy (ventricular weight/body weight ratio [VW/BW]), left ventricular enlargement (volume at end-diastolic pressure equaled zero/body weight ratio [VO/BW]), and ventricular function (isovolumetric developed pressure, dp/dt, -dp/dt). A lowest mortality rate in the animals treated with the combination of both ACE inhibitor and AT1 receptor antagonist was observed. Although lisinopril and losartan significantly decreased VW/BW ratio, when administered concomitantly, VW/BW ratio was lower than when either agent was administered individually. There were no differences in right ventricle hydroxyproline concentration. Only combination therapy decreased VO/BW ratio. The treatment with lisinopril plus losartan resulted in increases in the development of pressure versus untreated group; without alteration in dp/dt and -dp/dt. Conclusions: The combination of the AT1 receptor blockade and ACE inhibitor is more effective than individual treatment on ventricular remodeling and survival after MI in rats.
publishDate 2000
dc.date.none.fl_str_mv 2000-01-01
2022-04-28T19:54:58Z
2022-04-28T19:54:58Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1054/JCPT.2000.7450
Journal of Cardiovascular Pharmacology and Therapeutics, v. 5, n. 3, p. 203-209, 2000.
1074-2484
http://hdl.handle.net/11449/224157
10.1054/JCPT.2000.7450
2-s2.0-0033915319
url http://dx.doi.org/10.1054/JCPT.2000.7450
http://hdl.handle.net/11449/224157
identifier_str_mv Journal of Cardiovascular Pharmacology and Therapeutics, v. 5, n. 3, p. 203-209, 2000.
1074-2484
10.1054/JCPT.2000.7450
2-s2.0-0033915319
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Journal of Cardiovascular Pharmacology and Therapeutics
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 203-209
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1799964580108042240